biodynamictissue
Transcription
biodynamictissue
b i o d y n by distributor Via delle Industrie 2/4 - 30020 Marcon (VE) Italy tel. +39 041 5020370 - fax +39 041 5020366 info@decomed.it - www.protexa.it a m i c t i s s u e b i o d y n a m i c t i s s u e Tecnoss, an Italian company with a site in Turin is a leader in the tissue bioengineering sector. Thanks to its patents (ECPT) it has been deantigenizing heterologous matrixes for 15 years, and distributing its biomaterials in 40 countries around the world. 350,000 implants to date. DECOmed, an Italian company with a site in Venice has been present in the medical-surgical market since 1989. Distributing specialist and high technology products throughout Europe. Tecnoss and DECOmed present Protexa, an Italian project set up in 2008 and developed in collaboration with surgical specialists: supplying safe, high technology products at an accessible price. Protexa. Made in Italy. www.protexa.it info@decomed.it b i o d y n a m i c t i s s u e Your Mastery... The ‘direct’ repair of the ventral hernia is hindered by the high percentage of recurrences due to the tension exercised on the fascia of the suture and to the conditions of the tissue tropism. Since the first half of the 900’s the most diverse and inert materials have been researched for use in the closure of a wound or incision without placing tension on the fascia. Only in the second half of the 900’s was polypropylene used, having been shown to be the most fit for this purpose. There are also meshes in polypropylene adapted for coming into contact with the bowel loops, and in polyester coated with absorbable substances which facilitate the rehypertonization, some coated in silicone, others in PTFE. The problem with this type of prosthesis is the fact that, although inert, it is a foreign body and these can bring complications such as infection, fistulization and erosion of the skin. There are some predisposing conditions to infection which put the successful outcome of the implantation at risk. In order to prevent this, it is imperative to be able to trust in a mate- Is it possible a more enlarged indication? rial which gives us the same guarantee as a synthetic prosthesis (resistance to tension, malleability, biocompatibility, allergy resistance), but doesn’t behave as foreign body. Biological prostheses is a category which incorporates all of these characteristics, but at the same time guarantees better protection against infection. which is fixed around the circumference of a wound or incision with re-absorbable stitches so as to keep it in position. The biological prosthesis offers the guarantee that once implanted, it becomes a structure recognized by the organism. It becomes revascularized and reinforces the deficit in the fibrotic structure. The site of the positioning of the organic prosthesis is similar to that of a synthetic mesh, The application of this material is therefore used electively in all cases where there is po- tential contamination of the wound (the presence of a colostomy, tearing of the intestine, a history of infection of the site) Should the producers of the product render it more accessible in terms of cost, it would be available for more widespread use also in patients at risk from potential infection due to comorbidity (immunodeficiency, advanced age, nutritional state, diabetes, obesity, corticosteroid therapy etc.) b i o d y n a m i c t i s s u e ...our background For 15 years the Tecnoss laboratory of Turin has been deantigenizing under its own heterologous matrix patent. In forty countries all over the world, surgical specialists use Tecnoss biomaterials. To date, more than three hundred and fifty thousand implants. This expansion in the market has effectively absorbed the cost of the research, and today, has allowed the extension of the use of a biological prosthesis which meets economical needs along with the need for more advanced surgical performance. FAQ Q: Can the biological prosthesis be reabsorbed, allowing the hernia to reform? A: No. The prosthesis constitutes a support which re-enforces the abdominal wall, being recognized, revascularized and becoming a substitute for the missing tissue. Q: Can the prosthesis be rejected? A: No. The prosthetic material is properly treated (deanitgenized). It is a natural constituent of the organism, and in this way is perfectly biocompatible. Q: Can the prosthesis be encapsulated as a foreign body? A: No. Being completely biocompatible, it becomes revascularized and entirely accepted. For this reason even its macroscopic recognition can be difficult in the case of revision. Q: Can the prosthesis be used for when performing Miles’operation? A: Yes. Since it acts as a filler, it can be used both for closure after the pelvic exploration in laparoscopy, and open surgeries. It can also be used to reinforce the posterior band of the ano praeter. Q: Are there clinical indications for using the biological prosthesis during the Nissen fundoplication for hiatus hernia? A: Yes. The organic prosthesis is perfectly adapted for reinforcing the proximity of the diaphragmatic pillars, also in the case of revision, or to bridge the gap should the pillars be too far apart. Q: Can the prosthesis be used for, and how do they function in pelvic floor reconstruction surgery? A:They can assuredly be used and give more security in cases at risk of infection due to the accidental opening of the colon and/or vagina. Q: Can the biological prosthesis be used in cases in which there is the presence of macerated skin, problems of regeneration of the tissues, proximity of the stomy? A: Yes. The biological prosthesis provide the best guarantee against risk of infection, and it is therefore possible to use it also in the presence of colostomy (parastomal hernia) in patients with ascites, macerated skin and dystrophic tissue. Q: Is it possible to use the prosthesis for immunodepressed patients? A: Yes. Ventral hernias in transplant patients are relatively common, and the dilemma of choosing whether or not to use prosthetic materials which may be the cause of infection, is resolved by using a biological prosthesis. Q: How does the biological prosthesis perform when used with Trocar? A: It performs excellently. It is easy to roll and insert into the trocar, and likewise as easy to extract and extend. b i o d y n a m i c t i s s u e Guided tissue regeneration The structural integrity of the extracellular matrix: A key factor in its clinical success These characteristics of the Tecnoss manufacturing process more than adhere to the safety requirements; a substantial cellular and vascular colonization of Protexa, for close contact and a gradual remodeling of the endogenous neo-tissue. In fact, it is the collagen preserved in the integrated extracellular matrix which has a fundamental role in the tissue regeneration, as: a) It acts as a sound substrate for platelet activation and aggregation; b) It is able to attract and stimulate the differentiation of mesenchymal stem cells in the bone marrow; c) It increases the levels of proliferation of fibreblasts by 2/3 times ; d) Contact with it promotes the aggregation and subsequent platelet lysis, which is the very first stage of tissue healing. 1)Salasznyk RM, et al. Journal of Biomedicine and Biotechnology (2004), 1:24-34 2) Hsu FY, et al. Biomaterials (1999), 20: 1931-1936 The identification of the sequence of events which bring about guided tissue regeneration has allowed us to indentify the key factors in the process of guiding; the simultaneous presence of three fundamental components is the prerequisite for the ‘de novo’ formation of tissue. –The platelets are the key players during the first phase of the healing process, when, following a lesion, initially a fibrin deposit and the formation of blood clots take place; This stage is characterized by significant activation of the chemical signs mediated by cytokines and growth factors. In fact, the primary post haemorrhagic clot formation process through platelet aggregation and lysis, determines the release of both the coagulation cascade factors and of the growth factors including PDGF, I’IGF1, I’IGF2, AND VEGF, which are known for their activating effects on fibroblasts. –The fibroblastic precursors are derived from mesenchymal bone marrow stem cells, once they are differentiated fibroblasts through collagen synthesis and other components of the extracellular matrix, they become responsible for the second phase of the guidance process. – An insoluble substrate, which acts as a suitable foundation to the process of tissue regeneration, and carries out the support functions and guidance of the formation of new tissue. For example an integrated extracellular matrix. The continued progress in the comprehension of biological mechanisms which regulate morphogenesis of the tissue can also be capitalized on. They can aid the development and expansion of both natural and artificial products able to restore or maintain the function of damaged tissues and organs (tissue engineering) 1, 2, 3 1) Griffith LG, Naughton G. Science (2002); 295: 1009-14 2) Reddi AH. Tissue Eng (2000); 6: 351-59 3) Nakashima N, Reddi AH. Nature Biotechnology (2003); 9: 1025-32 b i o d y n a m i c t i s s u e The Product Characteristics: a Collagen membrane obtained from porcine dermis, using the exclusive process of Enzymatic-Chemical-Physical Treatment at Low Temperature (ECPTLT). Its consistency and resistance allow perfect stabilization, as well as prolonged protection of the receiving site after draining and suturing the surgical flaps. Clinical Indication. A matrix of biological tissue to repair, support and regenerate sections of lost tissue, either as membrane protection, or as partial or full reconstruction and recovery of the sections of tissue lost. Packaging. Double packaged in sterile, single use form. Sterilization. Product sterilized by gamma ray. Warning. The product has not been tested on pregnant patients. Safely from nature to man Tecnoss develops and manufactures animal-derived biomaterials from which they originate new concept medical devices intended to provide valuable and innovative aids which assist the surgeon and give clinical benefits to the patient. A special technology is used in the preparation of the materials. This technologyenables the neutralization of antigenic products present in animal tissue (achieving biocompatibility), allowing you to obtain unique products which meet every surgical need. Thanks to Tecnoss’ biomaterials it is possible to obtain excellent results in healing, characterized by active colonization of the recipient site by the cells of the patient in order to facilitate the process of fully recovered injured tissue. The raw materials which Tecnoss uses in its products derive from Italian raised animals, selected and certified under the control of the Servizio Sanitario Nazionale Veterinario (The national veterinary sanitation service). Tecnoss biomaterials conform to the production regulations of the European Directive 93/42/CEE (D.Lgs 47/97 and Modified Directive 2007/47/CEE), 2003/32/CE (D.Lgs 67/2005). The Istituto Superiore di Sanità (The Higher Institute of Health) is the notified body (0373) for the CE mark of Tecnoss’ medical devices. The organic matrix from which Tecnoss’ line of medical devices is derived is subject to ISO 10993, which is a series of biological and histocompatibility tests from which the complete and perfect bioavailability and biocompatibility of the products have emerged. Instructions for use. Open the packaging and immerse the membrane in a tepid, sterile saline solution for 15-20 minutes. After adapting the membrane to the required shape and size using sterile instruments, position it onto the receiving site, and proceed with the suture of the surrounding tissue. Should the product be exposed, its removal is recommended only in the presence of an evident superinfection, as the size and nature of the product allow healing of the wound by secondary intention. b Histological Examination Protexa i o d y a m i c t i s s u e Protexa Samples of deantigenized porcine collagen prosthesis using the Tecnoss method. The histological preparations were set up using an uncontaminated sample of Tecnoss Dermis (Protexa) hydrated according to the instructions for use on patients, subjected to brief fixation (1 hour) in formalin, processed according to standard procedures and stained in hematoxylin-eosin. n A sample of tissue taken six months after implantation, during unrelated surgery. The fibrous-connective tissue of the patient and porcine collagen membrane obtained by the Tecnoss method can be recognized. There is a complete absence of inflammatory reaction on the interface between the prosthesis and autologous tissue. AUTOLOGOUS TISSUE AUTOLOGOUS TISSUE The histological examination demonstrates that the prosthesis consists solely of collagen fibres without cellular elements. The colonization of the prosthetic membrane by newly formed tissue can be seen, exhibited by the presence of newly formed vessels or fibroblastic cells, highlighted by vimentin, between the collagen fibres of the membrane protex. The lack of inflammatory reaction, demonstrated by the presence of few lymphocytes can be appreciated. Immunohistochemical investigations demonstrated a negative result both for vimentin and CD31. Vimentin: is one of the five cytoplasmic intermediate filaments (MW 57,000). and present in mesenchymal cells such as fibroblasts, endothelial cells and smooth muscle cells. By kind permission of Prof. A. Iannucci Verona, Italy Protexa Protexa By kind permission of Prof. A. Iannucci Verona, Italy b Clinical Indications which was accentuated during straining. It was decided to repair the area of weakness using biological prosthetic material (Protexa) as closing first was not feasible and the use of another type of synthetic graft was considered, given the anatomical location, to be putting the patient at high risk of infection. Protexa Patient underwent protective colostomy performed during an operation for intestinal resection and reconstruction performed in emergency for perforated diverticulum. Some months later the patient developed a significant ventral hernia. The surgical program was to restore the intestinal continuity, close the ostomy, and to concurrently conduct a massive incisional hernia repair. Given the possibility of infection with a synthetic graft, the use of a biological prosthesis (Protexa) was decided upon. By kind permission of Doctor U. Tedeschi. Verona, Italy Protexa Patient underwent amputation of the coccyx due to painful subluxation following a fall. In the area of the coccyx a symptomatic hernia can be seen with herniation of the rectum, i o d y n a m i c t i s s prosthesis (Protexa) was also used to bridge the fascial defect. By kind permission of Doctor U. Tedeschi. Verona, Italy Protexa Patient operated on for anterior resection due to rectal cancer in December 2006. During surgery was subjected to IntraOperative Radiation Therapy (IORT). The foreseen post-operative radiotherapy was carried out. The patient suffered an anastomotic leakage with entero-cutaneous fistula. For this reason a colostomy was given. Anastomotic dehiscence slowed the healing process, delaying recanalization. Meanwhile a parastomal hernia and a middle incisional hernia developed. The surgical program was to restore the intestinal continuity, closing the stoma, and to concurrently repair the massive hernia. Given the possible infection of any synthetic graft, the use of the biological prosthesis was decided upon. It was decided to first repair the hernia, excluding the site of the stoma and subsequently recanalize the patient. A piece of biological e Certification and references By kind permission of Doctor U. Tedeschi. Verona, Italy Protexa u Male patient suffering from Crohn’s disease had previously been given a sigma resection in 1997, accessed via right pararectal, and right hemicolectomy and ileal resection in 2004, via Xiphopubic midline incision. The patient came under observation for a terminal stenosis due to ileal segment and a fistula enterocutanea. During intervening periods had undergone surgery and medical therapies (anticancer drugs, steroids, immunosuppressants and monoclonal antibodies). It should be noted that following the two surgical operations the patient had a xiphoumbilical hernia with atrophy of the right rectus abdominis by denervation. The patient underwent surgery due to vascular insufficiency consisting of resection of the stenotic tract and ileal tract and of the remaining transverse colon via middle xipho- pubic approach. For abdominal restraint a biological prosthesis (Protex) was opted for due to the high risk of infection. By kind permission of Doctor R. Merenda. Mestre (VE), Italy Product code Product description Sizes Quantities ED10PS porcine dermis 10 cm x 10 cm x 1,4 mm 1 piece per package ED07PS porcine dermis 14 cm x 8 cm x 1,4 mm 1 piece per package ED20PS porcine dermis 20 cm x 10 cm x 1,4 mm 1 piece per package ED24PS porcine dermis 25 cm x 18 cm x 1,4 mm 1 piece per package ED32PS porcine dermis 30 cm x 20 cm x 1,4 mm 1 piece per package www.protexa.it 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 9 8 7 6 5 4 3 2 2 13 12 11 10 ED10 PS 19 18 17 16 15 14 ED07 PS ED24 PS distributor 29 28 27 26 25 24 23 22 21 20 ED20 PS Via delle Industrie 2/4 - 30020 Marcon (VE) Italy tel. +39 041 5020370 - fax +39 041 5020366 info@decomed.it - www.protexa.it 18 19 20